Celltrion Reports Positive Rheumatoid Arthritis Data From Subcutaneous Infliximab

 
• By Akriti Seth

New data presented by Celltrion at EULAR 2019 suggest that its subcutaneous formulation of infliximab is comparable to the intravenous version in treating rheumatoid arthritis.

Hands_Arthritis
Celltrion’s subcutaneous formulation of infliximab is comparable to the intravenous version in rheumatoid arthritis • Source: Shutterstock

More from Biosimilars

More from Products